PCSK9 Sponsors Still Face Challenges In Turning Around Dismal Launches

11 May 2017

• By Emily Hayes

After reporting yet another quarter of disappointing sales, Amgen and Sanofi/Regeneron look forward to better performance now that outcomes data are out, but payers may not be up for easing hurdles enough.

The first quarter of 2017 brought yet more disappointing sales figures for Amgen Inc.'s Repathaand Sanofi/Regeneron Pharmaceuticals Inc.'s Praluent, but the sponsors are hopeful for better uptake of the PCSK9 inhibitors through improved reimbursement policies on the back of new outcomes data.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble

18 Apr 2025

• By Alaric DeArment

The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.

Camzyos nHCM Failure Could Open Door To Threat From Cytokinetics’ Aficamten

15 Apr 2025

• By Alaric DeArment

BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.

Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly

15 Apr 2025

• By Andy Smith

The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.